EOP cash flow target $200M+, record DKL EBITDA, SRE/RIN monetization, 2026 guidance & risks—read insights now.
WAVE Life Sciences (NASDAQ:WVE) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight ...
Wave, marked by positive clinical data sets in obesity and AATD that further demonstrated the broad potential of our unique ...
General and administrative expenses were $1.7 and $5.6 million for the quarter and twelve months ended December 31, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results